CF
CPRX

Centaurus Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Centaurus Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
7,184
-65
-0.9% -$1.92K 0.01% 840
2026
Q1 		$179K Buy
7,249
+100
+1% +$2.38K 0.01% 850
2025
Q4 		$167K Sell
7,149
-675
-9% -$15K 0.01% 863
2025
Q3 		$154K Buy
7,824
+150
+2% +$3.08K 0.01% 884
2025
Q2 		$167K Sell
7,674
-103
-1% -$2.43K 0.01% 784
2025
Q1 		$189K Buy
7,777
+37
+0.5% +$833 0.01% 689
2024
Q4 		$162K Sell
7,740
-1,795
-19% -$38.6K 0.01% 722
2024
Q3 		$190K Sell
9,535
-100
-1% -$1.85K 0.01% 653
2024
Q2 		$149K Sell
9,635
-200
-2% -$3.11K 0.01% 678
2024
Q1 		$157K Buy
+9,835
New +$148K 0.01% 665

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centaurus Financial's CPRX Position: Q2 2026 in Review

Centaurus Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 0.9% in Q2 2026, selling an estimated $1.92K and leaving 7,184 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #840.

Centaurus Financial first reported a position in CPRX in Q1 2024 and has held it in 10 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Centaurus Financial held 7,184 shares of Catalyst Pharmaceutical worth $226K as of Q2 2026.
  • Centaurus Financial sold 65 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.92K.
  • Catalyst Pharmaceutical made up 0.01% of Centaurus Financial's portfolio in Q2 2026, its #840 holding.
  • Centaurus Financial first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.